Doxazosin Tablet
Product Images NDC 68071-3811

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68071-3811). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3811 6)

Doxazosin 2 mg tablets packaging label from NuCare Pharmaceuticals, Inc. The label indicates the bottle contains 60 tablets. Tablets are described as round, biconvex, mottled light pink to pink, scored with '784' debossed on one side and a score line on the other. The label includes the product NDC 68071-3811, storage instructions, and warnings to keep out of reach of children.*

FDA Label Image

Doxazosin Tablets, Usp (92ead971 9de8 4240 B2c7 Fc2e9abac7dd 01)

Chemical structure diagram of the active ingredient Doxazosin, illustrating its molecular composition including aromatic rings, nitrogen-containing groups, and methoxy substituents, as well as a methanesulfonate moiety.*

FDA Label Image

Doxazosin Tablets (92ead971 9de8 4240 B2c7 Fc2e9abac7dd 02)

A comparative bar graph and table showing the effects of Doxazosin at varying doses (4 mg and 8 mg) versus placebo on symptom score and maximum flow rate in multiple clinical studies. The graph quantifies changes from baseline in symptom scores and urine flow rates, highlighting statistically significant improvements with Doxazosin treatment.*

FDA Label Image

Doxazosin Tablets, Usp (92ead971 9de8 4240 B2c7 Fc2e9abac7dd 03)

Two line graphs comparing Doxazosin and placebo over a 14-week treatment period. The left graph shows mean change in total symptom score from baseline, with Doxazosin demonstrating a greater reduction. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin showing a higher increase compared to placebo. Both graphs include error bars and sample sizes (N=50 for Doxazosin, N=47 for placebo).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.